Biostar Pharma, Inc.

This phase 2 trial is testing whether the combination of utidelone and capecitabine can shrink brain tumors in people with HER2-negative breast cancer that has spread to the brain. About 120 participants will receive either utidelone alone or with capecitabine. The main goal is t…